This article was originally published in The Gray Sheet
Conditional approval is received from FDA to begin a study of laser thermal keratoplasty for patients with overcorrection (hyperopia) resulting from photorefractive keratectomy or laser in situ keratomileusis (LASIK) treatments for myopia. Enrollment of 10 patients (five post-PRK and five post-LASIK) will begin at the Hunkeler Eye Center at the University of Kansas. The approval is conditioned upon minor changes to the company's study protocol. Sunrise will seek to expand the patient population after one-to-three month follow-up of the initial patient population is complete. The Fremont, California-based company will include data from the study in a premarket approval application, which is slated to be submitted sometime in 1999, for its Corneal Sparing LTK system for the correction of hyperopia, presbyopia and overcorrection resulting from PRK or LASIK
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.